{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ecallantide",
    "query": {
      "intervention": "Ecallantide"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T05:44:21.971Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01036659",
      "title": "Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Angioedema"
      ],
      "interventions": [
        {
          "name": "ecallantide - Kallikrein inhibitor that blocks the production of bradykinin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bernstein, Jonathan A., M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2010-05",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2012-03-09",
      "last_synced_at": "2026-09-04T05:44:21.971Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01036659"
    },
    {
      "nct_id": "NCT01343823",
      "title": "Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ACE Inhibitor Induced Angioedema"
      ],
      "interventions": [
        {
          "name": "ecallantide 60 mg",
          "type": "DRUG"
        },
        {
          "name": "ecallantide 30 mg",
          "type": "DRUG"
        },
        {
          "name": "ecallantide 10 mg",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "placebo match for 30 mg ecallantide arm",
          "type": "DRUG"
        },
        {
          "name": "placebo match for 10 mg ecallantide arm",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2011-06-01",
      "completion_date": "2012-06-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-09-04T05:44:21.971Z",
      "location_count": 39,
      "location_summary": "Montgomery, Alabama • Colton, California • Los Angeles, California + 33 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01343823"
    },
    {
      "nct_id": "NCT00457015",
      "title": "Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "ecallantide",
          "type": "DRUG"
        },
        {
          "name": "Phosphate Buffer Saline (PBS), pH 7.0",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2007-04-01",
      "completion_date": "2008-06-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-09-04T05:44:21.971Z",
      "location_count": 42,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Crescent City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00457015"
    },
    {
      "nct_id": "NCT00888940",
      "title": "Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bloodloss",
        "Surgical Procedures, Operative"
      ],
      "interventions": [
        {
          "name": "Ecallantide",
          "type": "DRUG"
        },
        {
          "name": "Cyklokapron(R)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 243,
      "start_date": "2009-06",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2015-08-10",
      "last_synced_at": "2026-09-04T05:44:21.971Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00888940"
    },
    {
      "nct_id": "NCT00262080",
      "title": "Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "ecallantide",
          "type": "DRUG"
        },
        {
          "name": "Phosphate Buffer Saline (PBS),",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2005-12-31",
      "completion_date": "2007-02-28",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-09-04T05:44:21.971Z",
      "location_count": 1,
      "location_summary": "Wheaton, Maryland",
      "locations": [
        {
          "city": "Wheaton",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00262080"
    },
    {
      "nct_id": "NCT00816023",
      "title": "A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bloodloss",
        "Surgical Procedures, Operative"
      ],
      "interventions": [
        {
          "name": "ecallantide",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 276,
      "start_date": "2009-03",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2015-08-11",
      "last_synced_at": "2026-09-04T05:44:21.971Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Aurora, Colorado + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00816023"
    },
    {
      "nct_id": "NCT01832896",
      "title": "Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema Types I and II"
      ],
      "interventions": [
        {
          "name": "Ecallantide subcutaneous dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-08",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2023-03-31",
      "last_synced_at": "2026-09-04T05:44:21.971Z",
      "location_count": 1,
      "location_summary": "Mineola, New York",
      "locations": [
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01832896"
    },
    {
      "nct_id": "NCT00456508",
      "title": "Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "ecallantide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2007-04-01",
      "completion_date": "2010-09-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-09-04T05:44:21.971Z",
      "location_count": 39,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Crescent City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00456508"
    },
    {
      "nct_id": "NCT00448864",
      "title": "Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blood Loss, Surgical"
      ],
      "interventions": [
        {
          "name": "Ecallantide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 75,
      "start_date": "2007-05-01",
      "completion_date": "2008-08-01",
      "has_results": true,
      "last_update_posted_date": "2019-06-25",
      "last_synced_at": "2026-09-04T05:44:21.971Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00448864"
    },
    {
      "nct_id": "NCT01059526",
      "title": "Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "ecallantide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2010-02-01",
      "completion_date": "2014-06-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-09-04T05:44:21.971Z",
      "location_count": 40,
      "location_summary": "Little Rock, Arkansas • Bell Gardens, California • Granada Hills, California + 35 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059526"
    }
  ]
}